key: cord-0692620-15go7q3l
authors: Pendyala, Praveen; Goglia, Alexander G.; Mattes, Malcolm D.; Grann, Alison; Huang, David; Wagman, Raquel T.; Yehia, Zeinab Abou; Yoon, Jennifer; Ennis, Ronald D.
title: Impact of the coronavirus disease 2019 pandemic on radiation oncology clinical decision making in a high-prevalence environment
date: 2021-03-04
journal: Adv Radiat Oncol
DOI: 10.1016/j.adro.2021.100680
sha: c75479c1646744fc2b6039473731a7061806e06b
doc_id: 692620
cord_uid: 15go7q3l

PURPOSE: To define how the coronavirus disease 2019 (COVID-19) pandemic impacted the role, timing, and delivery of radiotherapy in a high-prevalence region at the height of the initial U.S. outbreak. METHODS: We performed a retrospective review of all patients seen at three radiation oncology departments within the “XXXX” Health system in “XXXX” during the initial COVID-19 surge. Primary end points were to define and quantify COVID-related, radiation-specific care changes, and to identify predictive factors of experiencing COVID-related care changes. RESULTS: 545 cancer patients were seen during the study period, 99 of whom (18.1%) experienced >1 COVID-related care change. Radiation treatment (RT) delays were most common, accounting for 51.5% of all care changes. Physician-directed delays accounted for 41.2% of RT delays, while patient fears, COVID testing, and access barriers were responsible for 27.5%, 17.6%, and 13.7%, respectively. Patient age (p=0.040), intent of treatment (p=0.047), and cancer type (p<0.001) were significantly associated with experiencing a COVID-related care change, as we found that older, curative intent, and rectal cancer patients were more likely to experience care changes. On multivariate analysis, patient age remained significant when controlling for treatment intent and cancer type. CONCLUSION: Our study provides a perspective on how care was adapted to protect cancer patients during a pandemic while maximizing disease control. The positive correlation between age and likelihood of care changes may reflect extra precaution taken with older patients given their vulnerability to severe COVID illness; while the lower observed likelihood of COVID-related care changes among patients undergoing palliative RT may reflect either the more urgent needs addressed by palliative RT or may simply be logistical, as palliative radiation is often delivered in short courses with less exposure risk. It will be crucial to assess adaptations others have implemented and monitor how they impact patient outcomes.

The rampant spread of COVID-19, a pulmonary illness caused by the novel coronavirus SARS-CoV-2, has resulted in a global pandemic that continues to devastate communities around the world and upend daily life. Since the initial outbreak in Wuhan, China in December 2019, SARS-CoV-2 has infected over 24 million people in 216 countries or territories, costing over 800,000 lives [1] .

Navigating this public health crisis has been particularly challenging for cancer patients, who are not only grappling with the burden associated with their diagnosis but many of whom are also immunocompromised and thus more susceptible to severe COVID-19 illness [2] [3] . A nationwide analysis in China showed that cancer patients had a 3.5-fold increased risk of requiring mechanical ventilation or ICU admission relative to patients without cancer [2] .

While some cancer patients have elected to avoid treatment owing to fear of infection, others have faced increased barriers to seeking care due to the resource constraints caused by surges in COVID-19 hospital admissions [4] . Access to cancer treatment may have been particularly affected for patients in the United 

Working with a vulnerable patient population within a resource strained healthcare environment, the [Anonymized for Review] oncology community joined hospital systems around the world in facing the unprecedented task of weighing the benefits of vital cancer treatment against the risks of patient exposure to a potentially deadly virus. Although professional societies and individual hospitals have issued multiple sets of guidelines on how cancer care can be modified during the pandemic, the actual impact of the pandemic on patients seeking radiation therapy and treatment decisions by radiation oncologists has not been well explored [9] [10] [11] [12] [13] . Prior studies examining the impact of the pandemic on cancer care have been largely restricted to patient survey data or have primarily focused on the rate of adoption of telemedicine [4, [13] [14] [15] [16] [17] .

Based on [Anonymized for Review]'s location at the epicenter of the initial U.S. outbreak, we sought to systematically evaluate the impact of the COVID-19 pandemic on radiotherapy-related care at the [Anonymized for Review] Health system. We hypothesized that the role, timing, and delivery of radiation were modified for a significant proportion of cancer patients owing to a combination of patient fears, physician's efforts to minimize patient exposure, and the reallocation of hospital staff and resources. We also aimed to identify predictors of experiencing a radiation-related care change during the pandemic.

We performed an IRB-approved multi-institutional retrospective review of all patients seen at three [19] . The study cohort consisted of patients who were seen in consultation (including telemedicine consultations), undergoing treatment planning, or on active treatment during the period of interest. Patients seen in consultation, regardless of whether they J o u r n a l P r e -p r o o f proceeded with radiation, were included. We excluded patients who had completed treatment prior to the period of interest and were only seen for routine follow up visit during the study period. We also excluded patients who presented for benign conditions such as stereotactic radiosurgery for trigeminal neuralgia.

Within the cohort, patients who experienced any alteration in care relating to radiation therapy as a result of the COVID-19 pandemic were either identified through a review of patient charts or were prospectively captured by a group of attending radiation oncologists participating in the project. A care change was only considered COVID-related when specifically indicated in a patient's chart. Radiationrelated care changes were classified into the following categories: RT (radiation treatment) delay/deferments, RT omission, RT fractionation change, brachytherapy-specific change, RT course disruption, and RT in lieu of surgery.

RT omission indicated that patients either declined recommended treatment or were advised by their radiation oncologist against undergoing radiation because the risk of exposure was thought to outweigh the benefit of treatment. RT course disruption refers to a pause or premature discontinuation in radiation treatment due to patient fears of exposure, the need for COVID testing, or a positive COVID test. The RT in lieu of surgery category includes patients who were treated with definitive radiation as opposed to upfront surgery or patients who, prior to COVID, may not have been treated with radiation but who received RT owing to limited access to certain surgical procedures. We defined a brachytherapy-specific change as omission of a brachytherapy boost, replacement of a brachytherapy boost with an external beam radiation treatment (EBRT) boost, or a change in the timing of a brachytherapy boost in relation to the EBRT course.

Patient, clinical, and treatment characteristics were collected, including age, cancer type, intent (palliative or curative), overall stage, presence of comorbidities associated with a higher risk of severe COVID illness per the CDC[20], performance status, and receipt of concurrent chemotherapy. Descriptive J o u r n a l P r e -p r o o f statistics were performed to determine the percentage of patients who experienced a COVID-related change in care within the entire cohort. A CDC-defined comorbidity linked with severe COVID illness 5 was classified as the presence of >1 of the following: diabetes, heart failure, coronary artery disease, chronic obstructive pulmonary disease, chronic kidney disease, or obesity. To objectively measure the variable impact of the pandemic on different cancer types, the frequency of COVID-related changes that were not prompted by either patient fears or need for COVID testing was calculated for each cancer type.

Univariate and multivariate analyses with t-test (age), Chi-square test (all other univariate analyses), or bivariate logistic regression (all multivariate analysis) were performed to evaluate the association between patient, clinical, and treatment parameters and the risk of experiencing a COVID-related care change. All p values below 0.05 were considered significant. All data analyses were performed using SPSS statistical software package version 27 (IBM) or MATLAB (Mathworks).

We identified all 545 cancer patients seen in consultation, undergoing treatment planning, or on active radiation treatment at three radiation oncology departments in the [Anonymized for Review] system from 03/09/20-06/15/20 ( Table 1) . 99 patients (18.1%) experienced at least one radiation-specific care change attributable to the COVID-19 pandemic.

Radiation treatment (RT) delays were the most common, accounting for 51.5% of all COVID-related care changes (n=51), followed by RT fractionation changes (n=14), RT omissions (n=11), RT course disruptions (n=10), RT in lieu of surgery (n=9), and brachytherapy-specific changes (n=9). Four patients in the cohort tested positive for COVID-19 during the period of interest. Three of these patients tested positive prior to initiating RT, resulting in RT delays and one patient tested positive in the middle of RT, resulting in an RT course disruption.

J o u r n a l P r e -p r o o f 41.2% of all RT delays were directed by the physician to minimize patient exposure to the healthcare setting. Patient fears, the need for COVID testing, and barriers to accessing care were responsible for 27.5%, 17.6%, and 13.7% of RT delays, respectively. Examples of healthcare access barriers that contributed to RT delays include challenges with scheduling fiducial placement for prostate RT (n=3), disruptions in insurance coverage (n=3), limited availability of dentists to obtain necessary tooth extractions prior to head and neck (H&N) radiation (n=1), and delays in percutaneous endoscopic gastrotomy tube placements prior to H&N radiation due to OR closures (n=1). One patient with esophageal cancer who was uninsured and unable to enroll for charity care in a timely fashion was admitted to the hospital to initiate inpatient chemoradiation without further delay.

Among all patients who experienced an RT delay, 41% were started on systemic therapy prior to the initiation of RT. Five patients who chose to delay their CT simulation for adjuvant breast radiation due to fear of COVID exposure were started on adjuvant endocrine therapy (tamoxifen or anastrozole) soon after breast conservation surgery. 12 patients who experienced a physician-directed delay in RT were started on systemic therapy in the interim. For 9 of these 12 patients, the treatment paradigm was significantly modified so that a full course of systemic therapy alone could be completed prior to starting radiation. For example, two patients with unfavorable intermediate risk prostate cancer completed 6 months of androgen deprivation therapy prior to starting radiation, and seven patients with rectal cancer received either a full course of adjuvant FOLFOX chemotherapy prior to adjuvant chemoradiation or underwent total neoadjuvant therapy (TNT) with FOLFOX chemotherapy administered prior to chemoradiation.

Among the 11 patients for whom radiation therapy was omitted, eight elected to forgo RT and three were advised against RT by their radiation oncologist. All three patients who were advised against radiation were being evaluated for adjuvant RT for a CNS malignancy. Observation was recommended for two patients with Grade 2 meningioma following a gross total resection (GTR) because the risk of COVID exposure was thought to outweigh the local control benefit conferred by adjuvant RT. One elderly patient J o u r n a l P r e -p r o o f who underwent a GTR for an IDH mutated, MGMT hypermethylated glioblastoma underwent adjuvant chemotherapy alone without concurrent radiation.

We identified seven patients who may have been spared radiation in the pre-COVID setting but who received RT as part of their treatment course due to limited surgical options during the pandemic. One patient with Stage I glottic cancer whose first preference was to undergo transoral laser microsurgery instead received definitive RT alone. Two patients with gynecological malignancies underwent treatment with definitive RT as opposed to a hysterectomy, one with medically operable endometrial carcinoma and the other with Stage IB cervical squamous cell carcinoma. Two breast cancer patients whose initial management preference was total mastectomy with autologous reconstruction were instead managed with breast conservation therapy encompassing whole breast RT owing to limited access to reconstructive surgery. Two H&N patients with positive margins after initial surgical resection underwent postoperative chemoradiation instead of re-excision surgery owing to OR closures. We also identified two additional patients who typically would have received upfront surgery followed by adjuvant radiation but were instead managed with upfront radiation owing to OR closures. Both patients had T4a glottic cancer and were initially recommended a total laryngectomy followed by adjuvant radiation but instead pursued a larynx preservation approach with definitive chemoradiation.

As a result of the pandemic, fourteen patients underwent a more hypo-fractionated regimen than would typically have been performed at our institution. As an example, four patients with high risk prostate adenocarcinoma, who are typically treated at our institution with conventional fractionation to 79. We identified nine patients who underwent a change in brachytherapy-specific care. Four high risk prostate cancer patients who were initially planned for combined modality treatment with EBRT to the whole pelvis followed by a brachytherapy boost were instead managed with EBRT to the pelvis followed by a hypo-fractionated EBRT boost. For two prostate cancer patients who successfully completed combined modality treatment during the pandemic, their high dose rate (HDR) brachytherapy boost was deliberately scheduled prior to the EBRT course in anticipation of upcoming OR closures. Vaginal cuff brachytherapy was omitted for two patients with high intermediate risk endometrial carcinoma who would typically have been treated with EBRT plus brachytherapy.

The frequency of COVID-related care changes that were not prompted by either patient fears or the need for COVID testing varied by cancer type ( Table 2) . 70% of all rectal cancer patients who were seen during the study period experienced a physician-directed COVID-related care change, most commonly a change in the sequencing of treatment such that treatment was begun with neo-adjuvant FOLFOX rather the chemoradiation with a plan for chemoradiation to follow. 18.1% of prostate cancer patients experienced changes to the radiation plan, including short-term delays in CT simulations directed by the physician, administration of prolonged courses of ADT (>2 months) prior to RT, increased hypofractionation, and omission or change in timing of HDR brachytherapy boost treatments. 18.8% of glioma patients, 14.2% of cervical cancer patients, 13% of H&N cancer patients, and 12.9% of endometrial cancer patients experienced an alteration in care driven by either clinical decision-making of the individual radiation oncologist or hospital resource constraints. In contrast, no patients with primary J o u r n a l P r e -p r o o f lung carcinoma or an upper GI malignancy -including esophageal, hepatobiliary, or pancreatic cancerexperienced a COVID-related care change beyond those related to patient fears or COVID testing.

Patient age, intent of treatment, and cancer type were significant predictors of experiencing a COVIDrelated care change ( Table 2 ). The mean age of patients who experienced a COVID-related change was 64.8 years, while the mean age of those who did not experience a COVID-related care change was 61.0 years (p=0.040). Patients undergoing curative intent treatment were also significantly more likely to undergo a COVID-related care change than those undergoing palliative therapy (20.6% vs. 7.6%, p=0.047). Finally, we also found, relative to other cancer types, that rectal cancer was significantly associated with experiencing a COVID-related care change (p<0.001). On multivariate analysis, patient age remained significant when controlling for intent of treatment and cancer type. Notably, the presence of CDC-defined comorbidities linked with severe COVID illness[20], performance status, and overall stage did not demonstrate clear associations with the chance of experiencing a COVID-related care change.

Despite the flurry of guidelines released since the start of 2020 on how RT should be modified during the COVID-19 pandemic, the extent to which radiation-related care was actually altered for cancer patients at the height of the pandemic in COVID-19 hotspots remains unclear. We found that nearly one fifth of all patients seen at three radiation oncology departments located in the epicenter of the initial U.S. outbreak experienced at least one change in the role, timing, or delivery of radiotherapy.

An RT delay was the most common COVID-related care change experienced by patients in our study, accounting for 49% of all documented changes. 9.3% of patients experienced a delay in RT, which is similar to the frequency of RT delays reported in patient surveys conducted during the pandemic [4, 17] .

For example, in a survey of 600 breast cancer patients in the U.S. who were seeking care or on active J o u r n a l P r e -p r o o f treatment from 04/28/20-06/07/20, 5% of respondents indicated that they experienced a delay in radiation therapy specifically because of the pandemic [4] . In another survey of over 1200 cancer patients conducted by the American Cancer Society Cancer Action Network (ACS CAN) from 04/30/20-05/14/20, 37% of cancer patients reported a delay in some aspect of oncologic care [17] . In an ESTRO survey examining the impact of the COVID-19 pandemic on European radiation oncology centers, 65% of the surveyed departments reported a decline in patient volume primarily owing to delays or deferrals [21] .

Although several patients in our cohort elected to delay or defer radiation treatment, patient hesitation to present to the healthcare setting was responsible for only a minority of RT delays. Our finding that patient fears were not the dominant factor contributing to RT delays parallels the attitudes expressed by breast cancer patients in an Italian survey in which 72% of respondents ranked compromised access to timely cancer care as their "biggest fear" during the pandemic, as opposed to just 11.6% of patients whose principle fear was hospitalization secondary to COVID-19 infection [15] . In fact, the most common cause of delayed treatment in our study was the independent clinical judgement of the patient's radiation oncologist, with physician-directed delays accounting for nearly half of all delays. In the ACS CAN survey, 64% of cancer patients who experienced a COVID-related care change reported that the change was prompted by their health care provider, mirroring our finding that physician discretion was the largest driver of treatment delays [17] .

For nine patients in our study, their radiation and medical oncologists made a joint evidence-based decision to modify the sequencing of radiation and systemic therapy such that a full course of systemic therapy alone was administered prior to starting RT. The adoption of TNT for rectal cancer patients in our cohort, which entails the delivery of a full course of FOLFOX chemotherapy prior to radiation, can be justified by the findings of the phase III RAPIDO trial, which demonstrated improved rates of pathologic complete response (pCR), locoregional control, and distant metastases with a TNT approach than with upfront preoperative chemoradiation [22] . The decision to administer a prolonged course of ADT alone J o u r n a l P r e -p r o o f (>2 months) prior to RT for multiple prostate cancer patients in our cohort is supported by a phase III study that revealed no difference in biochemical relapse-free survival between patients who underwent four months of ADT prior to RT vs. those who started ADT concurrently with RT [23] . Furthermore, in a recently published analysis examining the implications of altering the sequence of prostate RT and ADT during the pandemic, delaying RT to 120-180 days after starting ADT was not associated with a decrease in overall survival [24] .

Some RT delays in our study illustrated the impact of new health care access barriers imposed by the COVID-19 pandemic. For example, some procedures that can be required before the initiation of RT (e.g., fiducial marker and PEG tube placements) were harder to schedule owing to redeployment of hospital staff and resources during the pandemic. In addition, multiple patients in our cohort experienced RT delays owing to loss of insurance coverage or increased difficulty obtaining charity care during the height of the pandemic, with one patient forced to start chemoradiation in the inpatient setting. According to the Economic Policy Institute, nearly 12 million people lost employer-sponsored health insurance between February and July of 2020, and the rate of RT delays observed in our study partially reflects the ripple effect of this unprecedented economic disruption on timely access to vital oncologic care [25] .

Beyond delaying treatment initiation, radiation oncologists employed multiple additional strategies to minimize patient exposure to the healthcare setting, including hypofractionation, elimination of a brachytherapy boost, or omission of RT altogether. Notably, the increased use of hypofractionation in our cohort is aligned with multiple recommendations released by professional cancer societies during the pandemic[9-11]. Physicians' decisions to omit RT were either guided by published phase III data or based upon ongoing randomized trials. For example, the recommendation to forgo radiation treatment for the elderly patient with MGMT hypermethylated glioblastoma is supported by the NOA-8 trial, which demonstrated superior event free survival among MGMT methylated patients who underwent temozolomide alone vs. radiation alone [26] .

Like many institutions across the country, the pandemic triggered a decline in the total volume of patients on treatment at [Anonymized for Review], as the average number of patients on treatment each day fell by 33% from January 2020 to April 2020. However, though the overall patient volume dropped, we identified a specific subgroup of patients for whom the role of radiation expanded as a direct result of the paucity of available surgical interventions during the pandemic [27] .

The impact of COVID-19 on radiation-related care varied noticeably across different tumor types. For example, while the pandemic significantly altered the treatment paradigm for 70% of rectal cancer patients, no care changes were implemented for patients with upper abdominal malignancies such as hepatobiliary or pancreatic cancers. To our surprise, no patients with lung carcinoma in our cohort experienced a COVID-related change in radiation-related care. One explanation for this finding may be that all lung cancer patients evaluated for radiation treatment in the three departments during the study period happened to be medically inoperable and therefore were never considered for surgery. Importantly, there are also no available data that could justify delaying radiation for lung cancer, in contrast to other cancer types with better prognoses such as breast and prostate cancer [28] .

We found that patient age and the intent of treatment were predictors of COVID-driven care changes, as older patients and patients undergoing curative treatment showed a significantly higher likelihood of experiencing an alteration in care than younger patients or those undergoing palliative radiation. The positive correlation between age and frequency of care changes in our study may reflect the extra precaution that was taken with elderly patients given their increased vulnerability to severe COVID illness [20] . According to the National Center for Health Statistics Mortality Reporting System, the frequency of COVID-19 hospitalizations for individuals over 85 years old was 513.2 per 100,000, compared to a rate of 136.1 per 100,000 for those aged 50-64 [29] . The lower likelihood of COVIDrelated care changes among patients undergoing palliative RT may be explained by the typically more J o u r n a l P r e -p r o o f urgent needs met by palliative RT. Furthermore, radiation oncologists may have considered the risk of exposure to be lower with palliative courses of radiation that tend to be shorter than most curative radiation regimens.

The main limitation of our study is that a retrospective review may miss changes in patient care that were not explicitly documented by the care team. However, we attempted to partially account for this limitation by enlisting a large team of attending physicians across all three departments at the study outset to prospectively build lists of patients whose care was modified as a result of the pandemic. It is also important to note that, because cases in [Anonymized for Review] started to fall rapidly by the end of May, the choice of 06/15/20 as the end date for the study may have added a number of patients to our cohort whose care was unaffected by the pandemic, thereby diminishing the proportion of patients recorded as undergoing a COVID-driven care change, and potentially underestimating the impact of the pandemic reported in this study [6] . While setting an earlier end date may have magnified the measured frequency of COVID-related care changes, our chosen end date corresponded with an official date set by the state government to mark the next phase of reopening, signifying a drop in the case rate. The chosen end date also allowed us to capture several patients who elected to delay their radiation consultation beyond the end of May and patients who experienced delays in obtaining insurance coverage during the pandemic.

Previous studies exploring the impact of the COVID-19 pandemic on the delivery of cancer care have thus far primarily been based on patient survey data [4, [13] [14] [15] . In contrast, by identifying care changes through an objective evaluation of the charts, our approach avoids multiple sources of bias that can potentially confound patient survey data, including patient recall bias and self-selection bias, which may inflate the reported frequency of COVID-related care changes[30].

To our knowledge, this is the first multi-institutional study to characterize the impact of the COVID-19 pandemic on the utilization of radiation therapy in the hardest-hit region of the U.S. Nearly 1/5 th of all patients in our study population experienced at least one radiation-related care change that was directly attributable to the pandemic. RT delays were the most common change observed, and close to half of all delays were directed by the treating physician. We successfully identified three predictors of COVIDrelated care changes, as older patients, patients being treated with curative intent, and patients with rectal cancer showed a significantly higher likelihood of experiencing a change in their radiation therapy regimen. By shedding light on the clinical decision making of radiation oncologists at the initial epicenter of the U.S. COVID-19 pandemic, our study offers valuable lessons on how oncologic care can be carefully adapted to ensure adequate protection from a widespread deadly pathogen while maximizing cancer control. We hope this study will help inform the development of treatment guidelines for this and future pandemics. This study, set at the epicenter of the initial U.S. COVID-19 outbreak, shows that nearly 1/5 of cancer patients seeking radiotherapy during the initial surge experienced a COVID-related care change. Notably, advanced age, curative intent, and rectal cancer were predictors of experiencing a care change. Taken together with long-term outcomes data and changes implemented by other groups, we hope this study will help inform the development of treatment guidelines for this and potential future pandemics.

COVID-19)

Cancer patients in SARS-CoV-2 infection: A nationwide analysis in China

Poor clinical outcomes for patients with cancer during the COVID-19 pandemic

COVID-19's Impact on Breast Cancer Care

Recommendations for triage, prioritization and treatment of breast cancer patients during the COVID-19 pandemic

Practice Recommendations for Risk-Adapted Head and Neck Cancer Radiation Therapy During the COVID-19 Pandemic: An ASTRO-ESTRO Consensus Statement

Practice recommendations for lung cancer radiotherapy during the COVID-19 pandemic: An ESTRO-ASTRO consensus statement

ILROG Emergency Guidelines for Radiation Therapy of Hematological Malignancies During the COVID-19 Pandemic

COVID-19 impact on timing of brachytherapy treatment and strategies for risk mitigation

The Impact of COVID-19 on Radiation Oncology Clinics and Patients With Cancer in the United States

The impact of the COVID 19 pandemic on breast cancer patients awaiting surgery: Observational survey in an Italian University hospital

Patient-reported treatment delays in breast cancer care during the COVID-19 pandemic

American Cancer Society Cancer Action Network

Certain Medical Conditions and Risk for Severe COVID-19 Illness

Effect of COVID-19 pandemic on practice in European radiation oncology centers

Short-course radiotherapy followed by chemotherapy before TME in locally advanced rectal cancer: The randomized RAPIDO trial

Sequencing of Androgen-Deprivation Therapy With External-Beam Radiotherapy in Localized Prostate Cancer: A Phase III Randomized Controlled Trial

Relative Timing of Radiotherapy and Androgen Deprivation for Prostate Cancer and Implications for Treatment During the COVID-19 Pandemic

Health insurance and the COVID-19 shock

Economic Policy Institute

Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: The NOA-08 randomised

COVID-19's Impact on Radiation Oncology-Initial Results of a Nationwide Physician Survey

Intervals Longer Than 20 Weeks From Breast-Conserving Surgery to Radiation Therapy Are Associated With Inferior Outcome for Women With Early-Stage Breast Cancer Who Are Not Receiving Chemotherapy

Older Adults and COVID-19. (n.d.). Retrieved

We thank all patients involved in this study for allowing us to learn from their experiences. We also thank all members of the Dept. of Radiation Oncology at Rutgers CINJ for their support and insight.